PMID- 33482923
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Jan 22
TI  - The delivery of hsa-miR-11401 by extracellular vesicles can relieve 
      doxorubicin-induced mesenchymal stem cell apoptosis.
PG  - 77
LID - 10.1186/s13287-021-02156-5 [doi]
LID - 77
AB  - BACKGROUND: Chemotherapy is an effective anti-tumor treatment. Mesenchymal stem 
      cells (MSCs), exerting therapy effect on injured tissues during chemotherapy, may 
      be damaged in the process. The possibility of self-healing through long-range 
      paracrine and the mechanisms are unclear. METHODS: Doxorubicin, a commonly used 
      chemotherapy drug, was to treat human umbilical cord-derived mesenchymal stem 
      cells (hUC-MSCs) for 6 h as an in vitro cell model of chemotherapy-induced 
      damage. Then we use extracellular vesicles derived from placental mesenchymal 
      stem cells (hP-MSCs) to investigate the therapeutic potential of MSCs-EVs for 
      chemotherapy injury. The mechanism was explored using microRNA sequencing. 
      RESULTS: MSC-derived extracellular vesicles significantly alleviated the 
      chemotherapy-induced apoptosis. Using microRNA sequencing, we identified 
      hsa-miR-11401, which was downregulated in the Dox group but upregulated in the EV 
      group. The upregulation of hsa-miR-11401 reduced the expression of SCOTIN, 
      thereby inhibiting p53-dependent cell apoptosis. CONCLUSIONS: Hsa-miR-11401 
      expressed by MSCs can be transported to chemotherapy-damaged cells by EVs, 
      reducing the high expression of SCOTIN in damaged cells, thereby inhibiting 
      SCOTIN-mediated apoptosis.
FAU - Li, Huifang
AU  - Li H
AD  - Nankai University School of Medicine, Tianjin, China.
AD  - The Key Laboratory of Bioactive Materials, Ministry of Education, Nankai 
      University, the College of Life Sciences, Tianjin, China.
FAU - Huang, Haoyan
AU  - Huang H
AD  - Nankai University School of Medicine, Tianjin, China.
FAU - Chen, Xiaoniao
AU  - Chen X
AD  - Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, 
      Beijing, 100730, China.
FAU - Chen, Shang
AU  - Chen S
AD  - Nankai University School of Medicine, Tianjin, China.
FAU - Yu, Lu
AU  - Yu L
AD  - Nankai University School of Medicine, Tianjin, China.
FAU - Wang, Chen
AU  - Wang C
AD  - Nankai University School of Medicine, Tianjin, China.
FAU - Liu, Yue
AU  - Liu Y
AD  - Nankai University School of Medicine, Tianjin, China.
FAU - Zhang, Kaiyue
AU  - Zhang K
AD  - Nankai University School of Medicine, Tianjin, China.
FAU - Wu, Lingling
AU  - Wu L
AD  - State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, 
      100853, China.
FAU - Han, Zhong-Chao
AU  - Han ZC
AD  - Jiangxi Engineering Research Center for Stem Cell, Shangrao, Jiangxi, China.
AD  - Tianjin Key Laboratory of Engineering Technologies for Cell Pharmaceutical, 
      National Engineering Research Center of Cell Products, AmCellGene Co., Ltd., 
      Tianjin, China.
AD  - Beijing Engineering Laboratory of Perinatal Stem Cells, Beijing Institute of 
      Health and Stem Cells, Health & Biotech Co, Beijing, China.
FAU - Liu, Na
AU  - Liu N
AUID- ORCID: 0000-0003-3832-5591
AD  - Nankai University School of Medicine, Tianjin, China. liuna@nankai.edu.cn.
FAU - Wu, Jie
AU  - Wu J
AD  - State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, 
      100853, China. wujie301@126.com.
FAU - Li, Zongjin
AU  - Li Z
AD  - Nankai University School of Medicine, Tianjin, China. zongjinli@nankai.edu.cn.
AD  - The Key Laboratory of Bioactive Materials, Ministry of Education, Nankai 
      University, the College of Life Sciences, Tianjin, China. 
      zongjinli@nankai.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210122
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (MicroRNAs)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Apoptosis
MH  - Doxorubicin/pharmacology
MH  - *Extracellular Vesicles
MH  - Female
MH  - Humans
MH  - *Mesenchymal Stem Cells
MH  - *MicroRNAs/genetics
MH  - Placenta
MH  - Pregnancy
PMC - PMC7821514
OTO - NOTNLM
OT  - Doxorubicin
OT  - Extracellular vesicles (EVs)
OT  - Hsa-miR-11401
OT  - Mesenchymal stem cells (MSCs)
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper.
EDAT- 2021/01/24 06:00
MHDA- 2021/07/06 06:00
PMCR- 2021/01/22
CRDT- 2021/01/23 05:27
PHST- 2020/09/22 00:00 [received]
PHST- 2021/01/11 00:00 [accepted]
PHST- 2021/01/23 05:27 [entrez]
PHST- 2021/01/24 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/01/22 00:00 [pmc-release]
AID - 10.1186/s13287-021-02156-5 [pii]
AID - 2156 [pii]
AID - 10.1186/s13287-021-02156-5 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2021 Jan 22;12(1):77. doi: 10.1186/s13287-021-02156-5.